BioMarin

YTD

ALL

Trade BioMarin 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About BMRN

BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307.

CEO

Alexander Hardy

CEOAlexander Hardy

Employees

3,401

Employees3,401

Headquarters

San Rafael, California

HeadquartersSan Rafael, California

Founded

1997

Founded1997

Employees

3,401

Employees3,401

BMRN Key Statistics

Market cap

13.10B

Market cap13.10B

Price-Earnings ratio

29.69

Price-Earnings ratio29.69

Dividend yield

—

Dividend yield—

Average volume

1.47M

Average volume1.47M

High today

$72.47

High today$72.47

Low today

$67.11

Low today$67.11

Open price

$70.00

Open price$70.00

Volume

4.35M

Volume4.35M

52 Week high

$94.85

52 Week high$94.85

52 Week low

$60.63

52 Week low$60.63

BMRN News

TipRanks 9h

BioMarin Pharmaceutical: Strong Growth Prospects with Strategic Initiatives Justifying Buy Rating

Analyst Yun Zhong of Wedbush maintained a Buy rating on BioMarin Pharmaceutical (BMRN – Research Report), retaining the price target of $94.00. Discover the Be...

Benzinga 12h

Why Is BioMarin Stock Trading Higher On Thursday?

On Wednesday, BioMarin Pharmaceutical Inc. BMRN reported fourth-quarter adjusted EPS of 92 cents, up from 49 cents reported a year ago, beating the consensus of...

TipRanks 14h

BioMarin Pharmaceutical: Strong Financial Performance and Promising Growth Prospects Warrant Buy Rating

In a report released yesterday, Kostas Biliouris from BMO Capital maintained a Buy rating on BioMarin Pharmaceutical (BMRN – Research Report), with a price targ...

Analyst ratings

79%

of 28 ratings

Buy

78.6%

Hold

21.4%

Sell

More BMRN News

TipRanks 15h

Strong Financial Performance and Strategic Growth Drive Buy Rating for BioMarin Pharmaceutical

Bank of America Securities analyst Jason Gerberry has reiterated their bullish stance on BMRN stock, giving a Buy rating today. Discover the Best Stocks and Ma...

TipRanks 15h

BioMarin price target raised to $126 from $122 at Piper Sandler

Piper Sandler raised the firm’s price target on BioMarin (BMRN) to $126 from $122 and keeps an Overweight rating on the shares following a Q4 top- and bottom-li...

TipRanks 1d

BioMarin reports Q4 non-GAAP EPS 92c, consensus 74c

Reports Q4 revenue $747M, consensus $711.05M. “Our operational transformation and strong financial execution in 2024 is the first step in BioMarin’s (BMRN) ambi...